Kidney Cancer Scotland
Cart
cabozantinib, new first line treatment for kidney cancer
Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or... Read More
Cabozantinib Effective in Real-World Analysis for Relapsed Mrcc
Cabozantinib is a safe and effective treatment option for patients with relapsed renal cell carcinoma (RCC) in every clinical practice, according to... Read More
CABOSUN trail shines for Cabozantinib
New CABOSUN Data Show Better PFS With Cabozantinib in mRCC Read the full article HERE Updated results from the phase II CABOSUN... Read More
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared... Read More
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup... Read More
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the drug cabozantinib (Cabometyx) be made... Read More
SMC approve of nivolumab and cabozantinib
Statement from Kidney Cancer Scotland on the news of the SMC’s approval of nivolumab and cabozantinib for late stage kidney cancer patients... Read More
Hopes for Cabozantinib NICE recommendation
Kidney Cancer UK is very disappointed to hear that at the midpoint of the Single Technology Appraisal (STA) of cabozantinib, NICE is... Read More
Cabozantinib unlikely to be recommended based on cost: NICE and Ipsen in talks
NICE and Ipsen are continuing to discuss whether cabozantinib (Cabometyx) is to be recommended for use on the NHS in England and Wales. Cabozantinib,... Read More
New drug cabozantinib for treating advanced kidney cancer under NICE review.
New drug cabozantinib, for use in treating advanced kidney cancer (approved by the FDA in the USA), is currently in the process of... Read More
CheckMate data support 1st nivo–cabo in advanced RCC
CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma (RCC) report... Read More
Cabo+Nivo combo gets positive CHMP recommendation
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma... Read More
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma... Read More
Cabo/atezo phase 3 combo RCC trial launched
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma... Read More
Drug combo hits targets in first-line RCC trial
Bristol Myers Squibb and Exelixis have announced that a late-stage study testing a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) has hit... Read More
Nivolumab+Sitravatinib Combo Impresses in RCC
Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary... Read More
Tivozanib Shows Superior Safety Profile Across TKIs in mRCC
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies... Read More
Over 20 Years of Kidney Cancer UK
For the over 20 years Kidney Cancer UK has been a consistent, prominent and influential name working to support patients through the... Read More
Setbacks and Advances in RCC Treatment
Given the variability in disease aggressiveness and the lack of highly predictive biomarkers in renal cell carcinoma (RCC), nothing resembling a “one... Read More
Outcomes of patients with mccRCC treated with 2nd line VEGFR-TKI
Prior to the approval of nivolumab, a monoclonal antibody targeting programmed death-1 (PD-1), vascular endothelial growth factor-receptor tyrosine kinase inhibitors (VEGFR-TKIs), specifically... Read More
How we work with N.I.C.E
How Kidney Cancer UK works with N.I.C.E to bring new drugs treatments to patients Author; Lucy Willingale Bsc (Hons) Oncology and Radiotherapy... Read More
Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC
OncLive reports that a trial in the USA of novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx)... Read More
Kidney Cancer UK represents patients at NICE appraisals
On the 10th May 2018 the National Institute for Care and Health Excellence (NICE) appraised two different drug treatments in two meetings. The... Read More
